Overview of Newer Glucocorticosteroid Preparations for Inflammatory Bowel Disease
Because the glucocorticosteroid receptor seems to be uniform in the human body, there is currently no support for a possibility of separating the therapeutic and adverse glucocorticosteroid actions at the receptor level. However, based on a new generation of glucocorticosteroids characterized by a h...
Saved in:
Main Author: | R Brattsand |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
1990-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/1990/708916 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease
by: Sara Jarmakiewicz-Czaja, et al.
Published: (2022-01-01) -
The use of oral topically acting glucocorticosteroids in the treatment of
inflammatory bowel disease
by: P. Rutgeerts
Published: (1998-01-01) -
Glucocorticosteroid in Treatment of Severe Pneumonia
by: Felinda Ariani, et al.
Published: (2013-01-01) -
Overview of 5-ASA in Therapy of Inflammatory Bowel Disease
by: CN Williams
Published: (1994-01-01) -
Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments
by: Bruno Rafael Ramos de Mattos, et al.
Published: (2015-01-01)